Back to results
US 2022/0008564 A1Published application
Radiopharmaceutical and methods
AssigneePOINT Biopharma Inc.
InventorJoe McCann
Life of this patent
Estimating the term…
Abstract
The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
Claims31
1-62. (canceled)
A pharmaceutical composition comprising:
- (a) a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA;
- (b) one or more ascorbate compounds.
A pharmaceutical composition comprising:
- (a) a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA;
- (b) one or more stabilizer compounds,
- wherein the composition at least substantially free of a gentisate acid adduct impurity.
A method for treating a patient suffering from cancer, comprising:
- a) admixing 1) lutetium-177, 2) EuK-Sub-kf-iodo-y-DOTAGA in the substantial or complete absence of a gentisate compound, and 3) one or more stabilizer compounds;
- b) heating the admixed 1) lutetium-177 and 2) EuK-Sub-kf-iodo-y-DOTAGA in the substantial or complete absence of a gentisate compound, wherein a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA is formed in the absence of a gentisate compound;
- and
- c) administering the complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA to the patient.
1 more element
A complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA, wherein the complex is free of an impurity having a retention time of approximately of 9 to 12 minutes by high-performance liquid chromatography.
Dependencies are inferred from the claim text.